S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.50
+1.82
+10.91%
SHC · Sotera Health Company
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Sotera Health Co (SHC)
NASDAQ NMS - GLOBAL MARKET
Life Sciences Tools & Services
$17.78
-0.15
(-0.86%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$17.78
$17.75
$18.12
52-WEEK RANGE
$17.78
$13.09
$19.85
What's happening
- SHC is down 0.86% today, trading at $17.78. — Live quote
- Volume today (249,216) is well below its 3-month average of 2,479,290. (Finnhub fundamentals)
- Reports earnings on 2026-11-10 (before market open), 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.26 actual vs. $0.24 estimated (+7.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 7
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SHC
+1.64%
vs S&P 500
-11.13%
1-YEAR RETURN
SHC
+7.30%
vs S&P 500
-7.26%
6-MONTH RETURN
SHC
+13.27%
3-MONTH RETURN
SHC
+3.05%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.26
Est. $0.24
BEAT +7.6%
2026-04-26 (Q1 2026)
$0.18
Est. $0.18
BEAT +2.1%
2026-01-26 (Q4 2025)
$0.26
Est. $0.24
BEAT +6.2%
2025-10-26 (Q3 2025)
$0.26
Est. $0.22
BEAT +17.8%
Valuation Measures & Ratios
Enterprise Value4$6.99B
Forward P/E517.93
PEG Ratio63.19
Price / Sales (TTM1)4.21
Price / Book77.60
EV4 / Revenue5.75
EV4 / EBITDA17.10
Profit Margin13.44%
Operating Margin32.63%
Return on Equity (ROE8)26.75%
Return on Assets (ROA9)5.03%
Avg Volume (3M)2,479,290
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $5.01B | $4.24B | $4.48B | $2.95B | $3.09B |
| P/E | 36.69 | 60.87 | 74.54 | 144.16 | — |
| Price/Sales | 4.15 | 3.72 | 3.91 | 2.65 | 2.90 |
| Price/Book | 7.53 | 6.82 | 8.14 | 5.77 | 7.46 |
| EV/Revenue | 5.63 | 5.32 | 5.52 | 4.35 | 4.70 |
| ROE | 20.52% | 11.20% | 10.92% | 4.00% | — |
| ROA | 4.13% | 2.15% | 1.89% | 0.64% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short14,748,380
Change from Prior Settlement+20.18%
% of Float—
Days to Cover (Short Ratio)6.75
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 9.2% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 13.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is +7.3%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-08-19; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SHC
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $321.4M | $280.0M | $311.3M | $294.3M | $254.5M | $285.5M | $276.6M | $248.2M |
| Gross profit | $178.0M | $147.1M | $177.6M | $166.6M | $135.4M | $158.0M | $152.8M | $127.1M |
| Operating income | — | — | — | — | — | $80.5M | $76.8M | $53.2M |
| Net income | $53.6M | $26.6M | $48.4M | $8.0M | -$13.3M | $17.0M | $8.8M | — |
| EPS (diluted) | $0.19 | $0.09 | $0.17 | $0.03 | $-0.05 | $0.06 | $0.03 | $0.02 |
| EPS (basic) | $0.19 | $0.09 | $0.17 | $0.03 | $-0.05 | $0.06 | $0.03 | $0.02 |
| Operating margin | — | — | — | — | — | $28 | $28 | $21 |
| Net margin | $17 | $9 | $16 | $3 | -$5 | $6 | $3 | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $3.31B | $3.24B | $3.26B | $3.19B | $3.22B | $3.10B | $3.07B | $3.15B |
| Total liabilities | $2.64B | $2.61B | $2.66B | $2.64B | $2.71B | $2.68B | $2.67B | $2.68B |
| Stockholders' equity | $665.6M | $622.5M | $606.0M | $550.5M | $511.3M | $414.1M | $404.9M | $470.2M |
| Total current assets | $646.5M | $586.0M | $613.4M | $577.8M | $608.2M | $555.0M | $526.0M | $563.6M |
| Total current liabilities | $231.2M | $207.8M | $249.6M | $242.4M | $246.3M | $226.0M | $191.0M | $195.5M |
| Cash & equivalents | $356.7M | $314.1M | $344.6M | $299.2M | $332.4M | $304.4M | $277.2M | $306.7M |
| Accounts receivable | $150.5M | $137.3M | $139.3M | $142.4M | $136.6M | $128.1M | $140.3M | $130.1M |
| Inventory | $56.4M | $57.5M | $54.4M | $49.9M | $59.9M | $61.0M | $49.2M | $53.6M |
| Other current assets | $9.7M | $9.3M | $13.1M | $8.5M | $9.5M | $11.9M | $8.2M | $9.3M |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | $1.09B | $1.10B | $1.10B | $1.10B | $1.10B | $1.08B | $1.08B | $1.10B |
| Intangible assets | $270.2M | $279.4M | $288.2M | $290.9M | $300.1M | $300.3M | $317.7M | $352.0M |
| Other non-current assets | $40.6M | $37.9M | $36.7M | $37.6M | $39.3M | $37.1M | $37.1M | $35.4M |
| Accounts payable | $101.0M | $76.7M | $78.0M | $61.4M | $63.7M | $70.1M | $55.1M | $70.8M |
| Accrued liabilities | $83.6M | $85.6M | $124.7M | $139.7M | $143.5M | $113.8M | $90.5M | $82.9M |
| Deferred revenue (current) | $14.2M | $13.7M | $18.0M | $14.1M | $11.5M | $13.8M | $15.1M | $10.7M |
| Short-term debt | $13.9M | $14.0M | $14.0M | $14.0M | $14.8M | $14.8M | $14.8M | $14.8M |
| Long-term debt | $2.13B | $2.12B | $2.13B | $2.13B | $2.20B | $2.21B | $2.21B | $2.21B |
| Other non-current liabilities | $5.4M | $5.2M | $7.4M | $7.0M | $7.2M | $5.5M | $4.4M | $9.3M |
| Common stock & paid-in capital | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M |
| Retained earnings | -$451.9M | -$505.5M | -$532.1M | -$566.9M | -$615.3M | -$623.3M | -$610.0M | -$622.4M |
| Accumulated other comprehensive income (loss) | -$143.5M | -$125.9M | -$109.8M | -$125.5M | -$108.3M | -$189.5M | -$208.3M | -$124.6M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $88.5M | $29.4M | $103.1M | $71.2M | $57.4M | $55.5M | $55.7M | $97.5M |
| Investing cash flow | -$43.3M | -$45.1M | -$50.7M | -$33.3M | -$31.2M | -$19.9M | -$65.9M | -$36.4M |
| Financing cash flow | -$2.4M | -$12.8M | -$8.2M | -$77.3M | -$6.9M | -$8.1M | -$6.5M | -$2.7M |
| Free cash flow | $42.0M | -$16.7M | $52.4M | $35.0M | $26.2M | $35.6M | -$10.2M | $61.1M |
| Capital expenditures | $46.4M | $46.2M | $50.7M | $36.2M | $31.2M | $19.9M | $65.9M | $36.4M |
| Depreciation & amortization | — | — | $94.9M | — | — | — | $84.3M | — |
| Share-based compensation | $7.2M | $14.4M | $7.6M | $7.9M | $8.1M | $7.2M | $8.1M | $9.8M |
| Deferred income taxes | $9.6M | $4.2M | $16.9M | $8.2M | -$9.0M | -$16.1M | $7.5M | $10.0M |
| Change in accounts receivable | $14.1M | -$891.0K | -$4.5M | $6.4M | $4.5M | -$13.6M | $14.0M | $6.0M |
| Change in inventory | $33.0K | $4.1M | $3.8M | -$9.0M | -$4.2M | $11.8M | -$1.5M | -$4.9M |
| Change in accounts payable | $10.6M | $2.8M | $8.0M | -$8.4M | -$6.1M | $11.7M | -$7.5M | $2.8M |
| Other investing activities | -$3.1M | -$1.0M | $0 | -$2.8M | $0 | -$37.0K | $0 | -$37.0K |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | $0 | $0 | $0 | — | $0 | $0 |
| Debt repaid | $0 | $3.6M | $3.6M | $75.0M | $3.8M | $3.8M | $3.8M | $0 |
| Tax withholding on stock comp | $272.0K | $8.8M | $2.7M | $207.0K | $54.0K | $3.6M | $2.1M | $166.0K |
| Other financing activities | -$1.3M | -$419.0K | -$1.5M | -$539.0K | -$789.0K | -$704.0K | -$672.0K | -$638.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.16B | $1.10B | $1.05B | $1.00B | $931.5M |
| Gross profit | $645.5M | $602.3M | $577.2M | $557.0M | $518.7M |
| Operating income | — | $297.6M | $276.7M | $248.3M | $256.7M |
| Net income | $77.9M | $44.4M | $51.4M | -$233.6M | $116.9M |
| EPS (diluted) | $0.27 | $0.16 | $0.18 | $-0.83 | $0.41 |
| EPS (basic) | $0.27 | $0.16 | $0.18 | $-0.83 | $0.41 |
| Operating margin | — | $27 | $26 | $25 | $28 |
| Net margin | $7 | $4 | $5 | -$23 | $13 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $3.26B | $3.07B | $3.13B | $3.12B | $2.79B |
| Total liabilities | $2.66B | $2.67B | $2.69B | $2.77B | $2.20B |
| Stockholders' equity | $606.0M | $404.9M | $443.7M | $350.2M | $586.1M |
| Total current assets | $613.4M | $526.0M | $557.2M | $645.0M | $346.0M |
| Total current liabilities | $249.6M | $191.0M | $230.7M | $791.6M | $161.2M |
| Cash & equivalents | $344.6M | $277.2M | $296.4M | $395.2M | $106.9M |
| Accounts receivable | $139.3M | $140.3M | $147.7M | $118.5M | $108.2M |
| Inventory | $54.4M | $49.2M | $48.3M | $37.1M | $54.3M |
| Other current assets | $13.1M | $8.2M | $10.8M | $9.1M | $7.3M |
| Goodwill | $1.10B | $1.08B | $1.11B | $1.10B | $1.12B |
| Intangible assets | $288.2M | $317.7M | $416.3M | $491.3M | $598.8M |
| Other non-current assets | $36.7M | $37.1M | $41.2M | $39.0M | $12.9M |
| Accounts payable | $78.0M | $55.1M | $71.0M | $74.1M | $72.9M |
| Accrued liabilities | $124.7M | $90.5M | $122.5M | $490.1M | $61.9M |
| Deferred revenue (current) | $18.0M | $15.1M | $13.5M | $12.1M | $8.7M |
| Short-term debt | $14.0M | $14.8M | $4.8M | $197.1M | $0 |
| Long-term debt | $2.13B | $2.21B | $2.22B | $1.75B | $1.74B |
| Other non-current liabilities | $7.4M | $4.4M | $8.9M | $12.8M | $16.3M |
| Common stock & paid-in capital | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M |
| Retained earnings | -$532.1M | -$610.0M | -$654.4M | -$705.8M | -$472.2M |
| Accumulated other comprehensive income (loss) | -$109.8M | -$208.3M | -$92.7M | -$106.7M | -$83.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $287.2M | $224.2M | -$147.7M | $278.0M | $281.5M |
| Investing cash flow | -$135.1M | -$179.0M | -$214.9M | -$181.9M | -$159.8M |
| Financing cash flow | -$100.5M | -$50.6M | $266.0M | $197.8M | -$117.3M |
| Free cash flow | $149.2M | $45.1M | -$362.7M | $95.6M | $179.4M |
| Capital expenditures | $138.0M | $179.1M | $215.0M | $182.4M | $102.2M |
| Depreciation & amortization | $94.9M | $84.3M | $76.6M | $64.3M | $64.2M |
| Share-based compensation | $30.9M | $36.8M | $32.2M | $21.2M | $13.9M |
| Deferred income taxes | $22.0K | $9.4M | $3.4M | -$74.0M | -$3.7M |
| Change in accounts receivable | -$7.2M | -$2.2M | $21.7M | $12.6M | $15.5M |
| Change in inventory | $2.4M | $4.8M | $10.0M | -$14.4M | $20.2M |
| Change in accounts payable | $5.2M | -$6.6M | -$5.3M | $1.1M | $19.8M |
| Other investing activities | -$2.9M | -$74.0K | -$69.0K | -$32.0K | $701.0K |
| Dividends paid | — | — | — | — | $0 |
| Share repurchases | — | — | — | $0 | $0 |
| Debt issued | $0 | $2.26B | $500.0M | $200.0M | $0 |
| Debt repaid | $86.1M | $2.26B | $2.5M | $0 | $100.0M |
| Tax withholding on stock comp | $6.6M | $4.4M | $4.1M | $393.0K | $1.4M |
| Other financing activities | -$3.5M | -$2.3M | -$1.8M | -$1.8M | -$642.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SHC as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-02 to 2026-08-17
Recent transactions
- Insiders have net sold 52,235,720 shares over the last 182 days, across 0 purchases and 6 sales.
- Most recent: Petras Michael B. Jr. (Executive Chairman) — Open market sale of 294,515 shares on 2026-08-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)52,235,720 sh(6 txns)
Net Shares-52,235,720
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Petras Michael B. Jr. | Executive Chairman | Open market sale | 2026-08-17 | 294,515 |
| Rutz Michael P | President of Sterigenics | Open market sale | 2026-08-07 | 150,000 |
| Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 2026-08-05 | 11,316 |
| SHADER ALTON | Chief Executive Officer | Grant / award | 2026-05-26 | 375,939 |
| Klee Ann R. | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| Kyle Richard G | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| Krause Kenneth D. | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| CUNNINGHAM SEAN LAURENCE | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| Flynn Karen | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| Neary James | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| PETRELLA VINCENT K | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| Chen Ruoxi | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| Simon, Christopher | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| Wheadon David E. | Reporting person | Grant / award | 2026-05-22 | 14,970 |
| WARBURG PINCUS & CO. | Director | Open market sale | 2026-05-13 | 19,102,952 |
| GTCR INVESTMENT XI LLC | Reporting person | Open market sale | 2026-05-13 | 12,735,301 |
| DIMITRIEF ALEXANDER | Former SVP, GC and Sec. | Tax withholding | 2026-03-31 | 7,941 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-17 | Petras Michael B. Jr. | Executive Chairman | Open market sale | 294,515 | $18.50 |
| 2026-08-17 | Petras Michael B. Jr. | Executive Chairman | Open market sale | 850,000 | $18.50 |
| 2026-08-07 | Rutz Michael P | President of Sterigenics | Open market sale | 150,000 | $18.84 |
| 2026-08-05 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 11,316 | $17.98 |
| 2026-05-26 | SHADER ALTON | Chief Executive Officer | Grant / award | 375,939 | $0.00 |
| 2026-05-26 | SHADER ALTON | Chief Executive Officer | Grant / award | 203,634 | $0.00 |
| 2026-05-22 | Klee Ann R. | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-22 | Kyle Richard G | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-22 | Krause Kenneth D. | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-22 | CUNNINGHAM SEAN LAURENCE | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-22 | Flynn Karen | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-22 | Neary James | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-22 | PETRELLA VINCENT K | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-22 | Chen Ruoxi | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-22 | Simon, Christopher | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-22 | Wheadon David E. | Reporting person | Grant / award | 14,970 | $0.00 |
| 2026-05-13 | WARBURG PINCUS & CO. | Director | Open market sale | 19,102,952 | $15.17 |
| 2026-05-13 | WARBURG PINCUS & CO. | Director | Open market sale | 19,102,952 | $15.17 |
| 2026-05-13 | GTCR INVESTMENT XI LLC | Reporting person | Open market sale | 12,735,301 | $15.17 |
| 2026-03-31 | DIMITRIEF ALEXANDER | Former SVP, GC and Sec. | Tax withholding | 7,941 | $14.34 |
| 2026-03-06 | WARBURG PINCUS & CO. | Director | Open market sale | 15,000,000 | $15.27 |
| 2026-03-06 | WARBURG PINCUS & CO. | Director | Open market sale | 15,000,000 | $15.27 |
| 2026-03-06 | GTCR INVESTMENT XI LLC | Reporting person | Open market sale | 10,000,000 | $15.27 |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 31,339 | $15.91 |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 40,302 | $15.91 |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Option exercise | 89,686 | — |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 39,552 | $15.91 |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 79,104 | $15.91 |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Grant / award | 240,248 | $0.00 |
| 2026-03-02 | DIMITRIEF ALEXANDER | SVP, General Counsel and Sec. | Tax withholding | 7,941 | $15.91 |
| 2026-03-02 | DIMITRIEF ALEXANDER | SVP, General Counsel and Sec. | Option exercise | 16,816 | — |
| 2026-03-02 | DIMITRIEF ALEXANDER | SVP, General Counsel and Sec. | Tax withholding | 23,619 | $15.91 |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 6,046 | $15.91 |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Option exercise | 17,937 | — |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 23,988 | $15.91 |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 8,240 | $15.91 |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Grant / award | 59,355 | $0.00 |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Tax withholding | 3,729 | $15.91 |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Tax withholding | 4,495 | $15.91 |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Option exercise | 14,573 | — |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Tax withholding | 17,497 | $15.91 |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Grant / award | 45,223 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:19 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-19 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-05 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-05-27 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-27 | 4 | 2026-05-26 | View on SEC.gov → |
| 2026-05-27 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-27 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-27 | 4 | 2026-05-22 | View on SEC.gov → |
| 2026-05-27 | 4 | 2026-05-22 | View on SEC.gov → |
Recent news
Headlines about SHC (Sotera Health Company). Links open the publisher — we don’t host full articles.
-
SHC serves notices over allegations of harassment against MPA
ARYnews.tv · 2026-10-22 -
Shaftesbury Capital's (SHC) "Buy" Rating Reiterated at Jefferies Financial Group
MarketBeat · 2026-10-21 -
Sotera Health Announces Third-Quarter 2026 Earnings Release Date
Yahoo · 2026-10-21 -
JPMorgan cuts target for Sotera Health stock from USD 18 to USD 17
AD HOC NEWS · 2026-10-20 -
2 Profitable Stocks to Keep an Eye On and 1 We Question
Yahoo · 2026-10-19 -
Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage
Seeking Alpha · 2026-10-14 -
JP Morgan Downgrades Sotera Health to Underweight, Announces $17 Price Target
Benzinga · 2026-10-14 -
Is Sotera Health (SHC) Still A Bargain After A 35% Gain?
Yahoo · 2026-10-09
No headlines in this category right now — try “All”.